-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.Börse Börse StuttgartSymbol DPL-
Dicerna PharmaceuticalsBörse Börse FrankfurtSymbol DPL
-
DICERNA PHARMACEUTICALS INCBörse Börse BerlinISIN US2530311081Symbol DPL
-
DICERNA PHARMACEUTICALS INCBörse Börse DüsseldorfSymbol DPL
-
DICERNA PHARMACEUTICALS INCBörse Tradegate System der Deutsche Börse AG (60%)Symbol DPL
-
DICERNA PHARMACEUTICALS INCBörse Börse StuttgartSymbol DPL
-
DICERNA PHARMACEUTICALS INCBörse Quotrix System der Börse DüsseldorfSymbol DPL
-
ISIN US2530311081 WKN: A1XCYUSymbol DRNA
-
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
1.951.917.824 oder 2.448.000.000
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
187 oder 302 Mitarbeiter
Entdecke die 6 ETFs in denen Dicerna Pharmaceuticals, Inc am höchsten gewichtet ist Insgesamt in 8 ETFs enthalten
Dir gefallen die Informationen zu Dicerna Pharmaceuticals?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Dir gefallen die Informationen zu Dicerna Pharmaceuticals?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Dir gefallen die Informationen zu Dicerna Pharmaceuticals?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Dir gefallen die Informationen zu Dicerna Pharmaceuticals?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
24 News & Informationen zur Dicerna Pharmaceuticals Aktie
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Au…
Dicerna Pharmaceuticals Inc (DRNA) President and CEO Douglas Fambrough Bought $110,500 of Shares
GuruFocus Article or News written by insider and the topic is about:
Royalty Pharma Reports Second Quarter 2021 Results
Strong growth in net cash provided by operating activities (GAAP) and Adjusted Cash Flow(2)Announced transactions of up to $2.8 billion in 2021, including…
A Peek Into The Markets: US Stock Futures Mostly Lower; Inflation Data In Focus
Pre-open movers
U.S. stock futures traded mostly lower in early pre-market trade. The U.S. Senate approved a $1.2 trillion infrastructure bill Tuesday that …
Dicerna Pharmaceuticals, Inc. (DRNA) CEO Doug Fambrough on Q2 2021 Results – Earnings Call Transcript
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Q2 2021 Earnings Conference Call August 09, 2021, 08:00 AM ET Company Participants Doug Fambrough – Chief Executive Officer Doug Pagan – Chief…
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of …
Dicerna Pharmaceuticals Q2 2021 Earnings Preview (NASDAQ:DRNA)
Dicerna Pharmaceuticals (NASDAQ:DRNA) is scheduled to announce Q2 earnings results on Monday, August 9th, before market open.The consensus EPS Estimate is $0.35 vs
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnin…
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.41% By Investing.com
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.41%
Why Dicerna Pharmaceuticals Stock Is Tumbling on Friday
A less than satisfying result from a phase 2 trial with nedosiran makes the company's future difficult to predict.
Mid-Afternoon Market Update: Dow Gains 140 Points; Spectrum Pharmaceuticals Shares Plummet
Toward the end of trading Friday, the Dow traded up 0.40% to 35,204.21 while the NASDAQ fell 0.41% to 14,833.72. The S&P also rose, gaining 0….
Dicerna Pharmaceuticals Drops on Mixed Drug-Trial Results
Dicerna Pharma in the fourth quarter expects to submit to the FDA a new-drug application for a treatment for hyperoxaluria, a genetic disorder.
Dicerna Announces FDA Clearance Of Investigational New Drug (IND) Application For DCR-AUD For The Treatment Of Alcohol Use Disorder
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi)
Were Hedge Funds Right About Service Properties Trust (SVC)?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors…
Dicerna Announces Interim Results From Phase 1 Trial Of Belcesiran For Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi)
Should I Avoid Infinera Corp. (INFN)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data….
Is Sun Country Airlines Holdings, Inc. (SNCY) Going to Burn These Hedge Funds?
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900…
Stocks Mixed Amid Earnings Reports, Powell and PPI
Stocks Analysis by Zacks Investment Research covering: Citigroup Inc, Bank of America Corp, Halliburton Company, Wells Fargo & Company. Read Zacks Investment Research's latest article on Investing.com
The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Ju…
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi)
EDGAR Filing Documents for 0001399529-21-000069
Veeva Becomes First Public Company To Convert To A Public Benefit Corporation
Veeva Systems VEEV announced that in an overwhelming majority vote, 99% of voting shareholders support the company's proposal to become a public benefit
Nonalcoholic Steatohepatitis Drug Pipeline Analysis Review, 2020
Los Angeles, USA , Jan. 13, 2021 (GLOBE NEWSWIRE) — Nonalcoholic Steatohepatitis Drug Pipeline Analysis Review, 2020
NASH Drug Pipeline Shows Promise as …
Dicerna Pharmaceuticals : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dicerna Pharmaceuticals, Inc. , a leading developer of investigational ribonucleic acid interference therapeutics, today announced that the Compensation Committee of the Company’s Board of… | January 4, 2021